NEW YORK (GenomeWeb News) – London Genetics and Astrimmune today announced a collaboration to identify predictive biomarkers for a pancreatic cancer vaccine being developed by Astrimmune.
The collaboration, being supported with a grant from the UK East Midlands Development Agency, will seek to identify biomarkers predictive of clinical response.
In a statement, the two firms said that Astrimmune's vaccine induces antibody production against gastrin, a hormone which stimulates the growth of many types of gastrointestinal cancer. Different response rates have been observed in clinical trials of gastrin-blocking products, "and there is a clear need for biomarkers to help identify those patients mostly likely to benefit from Astrimmune's product," they said.
Financial and other terms of the deal were not disclosed.